Methodology

How we collect

• Public surfaces — company websites, marketing pages, partner portals, social posts, and published news or ad alerts
• Official records — state board license lookups, FDA / FTC public databases, LegitScript website search screenshots
• Checkout documentation — non-purchase walkthroughs that capture payment hosts (e.g. PayPal and other checkouts) without completing a card charge when possible
• Patient / partner intake — this site’s Submit and Industry disclosure forms, including packaging images and COAs
• Correspondence — outreach letters to processors, pharmacies, and platforms; responses and documented non-responses may be published when cleared

Who we share with

Submissions include consent for regulatory research. That may include preparing packets for federal agencies, state boards and AGs, card networks and processors, and nonprofit / certification channels listed below.

• State boards & agencies hold licensing and enforcement power (inspect, discipline, civil AG action). Nonprofit, certification & consumer-integrity bodies tip, petition, certify, or publish — they do not replace a board complaint. NABP’s suspicious-site form is an association intake that can reach boards; it is not a substitute for filing with the patient’s or pharmacy’s state board.
• We share facts and exhibits relevant to each channel’s mandate (e.g. pharmacy boards get labeling / license issues; Visa / Mastercard packets focus on merchant risk and documented certification / compliance gaps, including public LegitScript listing status when relevant).
• We do not sell mailing lists or use submissions for commercial marketing.
• Contact emails and unredacted PII stay out of public web pages unless you later agree otherwise in writing.
• Criminal-threshold packages (e.g. FDA OCI) require counsel review before send.
• This site does not replace filing for yourself — we always recommend paralleling serious harms to FDA MedWatch, your state board, and 911 for emergencies.

Privacy & redaction

Redact your name, street address, Rx number, and full card data before uploading. Packaging photos may appear in evidence indexes only after PII review. We encourage crop-outs of postal labels while keeping pharmacy name, lot, BUD, and product strength visible when relevant.

Right of response

Named companies, pharmacies, processors, and individuals may reply. Factual corrections are noted. When outreach correspondence is published, responses and documented non-responses are logged with dates so the record stays complete.